Hackethal Johannes, Mühleder Severin, Hofer Alexandra, Schneider Karl Heinrich, Prüller Johanna, Hennerbichler Simone, Redl Heinz, Teuschl Andreas
1 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology , Vienna, Austria .
2 Austrian Cluster for Tissue Regeneration , Vienna, Austria .
Tissue Eng Part C Methods. 2017 May;23(5):274-285. doi: 10.1089/ten.TEC.2017.0016.
Pepsin-solubilized atelocollagen can be used to form highly complex three-dimensional matrices for a broad spectrum of tissue engineering applications. Moreover, it has a long history as a favorable biomaterial in pharmaceutical and medical industries. So far, the main sources for these approaches are collagens from xenogenic sources. Yet, these nonhuman collagens carry a risk of provoking immune reactions in patients. Here we describe an effective method of isolating atelocollagen type 1/3 (COL1/3) from human placenta. By combining a single pepsin digestion step with tangential flow filtration and further precipitation steps, we could purify COL1/3 within only 4 days of processing. The resulting COL1/3 was biochemically characterized by determining residual DNA content, proving the absence of impurities by sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS-PAGE) analysis combined with total amino acid quantification, identifying the isolated collagen types by Western blot analysis, and analyzing the spontaneous formation of fibrous structures on freeze-drying via scanning electron microscopy. Finally, the cytocompatibility of the isolated collagen was demonstrated in two dimensional using primary rat hepatocytes and in three dimensional by a sprouting assay of human umbilical vein endothelial cell. The isolation method described not only fulfills demands for cost-efficient bioengineering using a human waste material but also potentially increases overall safety for patients by use of homologous products.
胃蛋白酶溶解的去端肽胶原蛋白可用于构建高度复杂的三维基质,以用于广泛的组织工程应用。此外,作为一种良好的生物材料,它在制药和医疗行业有着悠久的历史。到目前为止,这些方法的主要来源是来自异种来源的胶原蛋白。然而,这些非人类胶原蛋白存在引发患者免疫反应的风险。在此,我们描述了一种从人胎盘中分离1/3型去端肽胶原蛋白(COL1/3)的有效方法。通过将单一的胃蛋白酶消化步骤与切向流过滤及进一步的沉淀步骤相结合,我们仅在4天的处理时间内就能够纯化COL1/3。通过测定残留DNA含量对所得的COL1/3进行生物化学表征,通过十二烷基硫酸钠/聚丙烯酰胺凝胶电泳(SDS-PAGE)分析结合总氨基酸定量来证明不存在杂质,通过蛋白质免疫印迹分析鉴定分离出的胶原蛋白类型,并通过扫描电子显微镜分析冻干时纤维结构的自发形成。最后,使用原代大鼠肝细胞在二维条件下以及通过人脐静脉内皮细胞的芽生试验在三维条件下证明了分离出的胶原蛋白的细胞相容性。所描述的分离方法不仅满足了使用人类废料进行经济高效生物工程的需求,而且通过使用同源产品潜在地提高了患者的整体安全性。